spacer
home > ict > autumn 2016 > credibility crisis
PUBLICATIONS
International Clinical Trials

Credibility Crisis

The Indian pharmaceutical sector has been cited as a “flagship” sector by Prime Minister Modi’s government. It has one of the highest numbers of FDA, Medicines and Healthcare products Regulatory Agency (MHRA) and WHO Good Manufacturing Practice (GMP) approved manufacturing facilities for medical ingredients and formulations outside the US and Europe (1). These facilities are responsible for a quarter of all medicines consumed in the UK and make nearly 40% of generic drugs and over-the-counter products sold in the US, as well as develop many drugs and vaccines used by global aid agencies for health programmes (2). On paper, the industry is blossoming – so why, in reality, is it in the middle of a credibility crisis?

Increasing Doubts

Regulators from across the globe are becoming more and more worried about Indian manufacturing practices, with 39 drug-making facilities having been blacklisted by the FDA over the past few years. In 2015 alone, six Indian drug makers lost clearance to produce medicines for US consumers due to regulatory problems, while the EU banned 700 Indian-made generic drugs – voicing concerns about the credibility of their clinical trials.

To add to this, the increase in the number of FDA warnings against Indian manufacturers has risen from 9 to 15 over the past two years, and the consequences of this are significant. Import bans and regulatory fines are levied for noncompliance, which can dramatically erode existing trust and reputation; two qualities that are extremely difficult to reclaim in a highly competitive global industry. Pharma companies worldwide are, therefore, beginning to review their alliance plans with Indian drug makers, and influential pharmacy benefit managers from the US already seem to be looking for alternatives to India, as they have started to wonder whether the risks actually outweigh the benefits. The FDA has also formally indicated that it has stepped up oversight and scrutiny of Indian drug traders.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vivek Chaturvedi is currently Vice President of the EMEA Chemicals Practice at Hitachi Consulting. He has worked in the chemicals and life sciences industry for over 15 years, leading and delivering large-scale operational transformation projects in a variety of global settings with Big Pharma, biotechnology, CROs and medical devices companies.
spacer
Vivek Chaturvedi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement